Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
In January 2026, a new outbreak of Nipah virus (NiV) was reported in West Bengal, India, drawing significant international attention. The WHO subsequently reissued a public health alert, highlighting the virus's exceptionally high case fatality rate of 40%–75% and its potential pandemic risk. Compared with the Ebola virus, NiV is characterized by a more insidious onset, a longer and variable incubation period, and a zoonotic transmission cycle, making early detection and containment considerably more challenging. Although initial symptoms are often nonspecific, the disease can rapidly progress to severe encephalitis or acute respiratory failure within a short timeframe.
With no approved therapeutics or vaccines, NiV remains a high-risk pathogen in virology and immunology research. Leveraging expertise in recombinant proteins, nucleic acid delivery, virus-like particles (VLPs), and antibody engineering, Creative Biogene has developed a systematic and modular portfolio of Nipah virus research products to support multi-level scientific investigation, from fundamental mechanisms to translational applications.
Nipah virus belongs to the family Paramyxoviridae, genus Henipavirus, and is an enveloped, single-stranded negative-sense RNA virus. Viral particles exhibit pronounced pleomorphism, with diameters ranging from approximately 40 to 600 nm. The NiV genome is approximately 18.2 kb in length, substantially larger than that of most classical paramyxoviruses, a feature that underlies its complex transcriptional regulation and pathogenic potential.
The NiV genome encodes the following proteins in a 3′ to 5′ orientation:
Figure 1. Structure of Nipah virus. (Singh RK, et al., 2019)
The N, P, and L proteins form the viral replication and transcription complex and are essential for maintenance of the viral life cycle. Through RNA editing, the P gene also gives rise to multiple non-structural protein variants, including the V, W, and C proteins. These proteins effectively antagonize host STAT1/STAT2 signaling pathways and constitute a key molecular basis for NiV-mediated suppression of innate immune responses and immune evasion.
The high pathogenicity of NiV is closely linked to its distinctive cellular entry mechanism. The viral attachment glycoprotein G, located on the viral envelope, specifically recognizes and binds to the host cell surface receptors ephrin-B2 and ephrin-B3. These receptors are highly expressed in endothelial cells, neurons, and multiple other tissues, providing a mechanistic explanation for the broad tissue tropism and pronounced neuroinvasive characteristics of NiV infection.
Figure 2. Cellular entry, tissue tropism, and neuroinvasion of Nipah Virus. (Al-Obaidi MMJ, et al., 2024)
Upon receptor engagement, the G protein undergoes conformational changes that trigger activation of the F protein. Following proteolytic cleavage by host enzymes, the F protein transitions from a prefusion to a postfusion conformation, driving direct fusion of the viral envelope with the host cell membrane and enabling efficient release of the viral genome into the cytoplasm.
Accordingly, the G and F glycoproteins are not only key determinants of NiV infectivity but also represent the most critical molecular targets for vaccine design, neutralizing antibody development, and receptor-blocking strategies.
Creative Biogene provides a standardized pseudovirus-based neutralization assay for functional evaluation of NiV entry inhibition. NiV G/F–pseudotyped viral particles carrying a reporter gene are pre-incubated with test samples (sera, plasma, monoclonal antibodies, or antibody fragments) and then applied to permissive target cells expressing ephrin-B2/B3. The reduction of reporter signal relative to virus-only controls determines neutralizing activity.
NiV G and F glycoproteins are co-expressed with a replication-defective, reporter-encoding viral backbone to generate pseudoviruses.
Neutralization Step
The mixture is added to ephrin-B2/B3–expressing target cells, and reporter signal is quantified to assess viral entry.
Data Analysis
Pseudovirus Production
Serially diluted antibodies or serum samples are pre-incubated with pseudovirus.
Cell Infection & Readout
Neutralization curves are generated, and inhibitory titers are calculated.
Quantitative neutralization readout
ID₅₀ / IC₅₀ values derived from dose–response curves.
BSL-2 compatible platform
no use of live Nipah virus.
Broad sample compatibility
serum, plasma, monoclonal antibodies, and antibody fragments.
Focusing on key molecular targets and experimental checkpoints throughout the NiV infection cycle, Creative Biogene has established a comprehensive product matrix encompassing recombinant antigens, mRNA-LNP formulations, virus-like particles, stable overexpression cell lines, functional antibodies, and molecular detection tools. This integrated portfolio provides standardized reagents that can be readily aligned with experimental designs at different stages of NiV research.
Creative Biogene offers multiple formats of NiV recombinant proteins, including full-length G protein and functional domains, F protein in distinct conformational states (pre-fusion and post-fusion), as well as the human ephrin-B2 receptor protein. These products enable receptor-binding analyses, immunogenicity assessments, and antibody screening under non-infectious conditions, providing reliable and reproducible materials for both fundamental and immunological studies of NiV.
| Cat. No. | Product Name | Target | Tag / Format | Sequence Region | Price |
| NPP-001 | Nipah Virus Glycoprotein G, His Tag | Glycoprotein G | His Tag | 71–602 | Inquiry |
| NPP-002 | Nipah Virus Glycoprotein G (Head Domain), His Tag | Glycoprotein G | His Tag | 178–602 | Inquiry |
| NPP-003 | Nipah Virus Pre-Fusion Fusion Glycoprotein, His Tag | Fusion Glycoprotein | His Tag | 27–487 | Inquiry |
| NPP-004 | Nipah Virus Post-Fusion Fusion Glycoprotein, His Tag | Fusion Glycoprotein | His Tag | 27–99 & 117–488 | Inquiry |
| NPP-005 | Human Ephrin-B2 Protein, His Tag | Ephrin-B2 | His Tag | 1–229 | Inquiry |
These products provide standardized antigen delivery tools for nucleic acid vaccine-related research, facilitating exploratory studies under non-infectious conditions.
| Cat. No. | Product Name | Target | Sequence Region | Price |
| NPR-001 | Nipah Virus Glycoprotein G mRNA-LNP | Glycoprotein G | 1–602 | Inquiry |
| NPR-002 | Nipah Virus Fusion Glycoprotein mRNA-LNP | Fusion Glycoprotein | 1–546 | Inquiry |
Virus-like particles retain the native spatial organization of viral surface antigens while lacking viral genomic material, thereby combining enhanced biosafety with high structural and biological relevance.
| Cat. No. | Product Name | Target | Sequence Region | Price |
| NPV-001 | Nipah Virus Glycoprotein G Full-Length Protein (VLP) | Glycoprotein G | 1–602 | Inquiry |
| NPV-002 | Nipah Virus Fusion Glycoprotein Full-Length Protein (VLP) | Fusion Glycoprotein | 1–546 | Inquiry |
Creative Biogene provides stable HEK293 cell lines overexpressing NiV G or F proteins, suitable for studies of viral entry and membrane fusion mechanisms, antibody or receptor-blocking assays, and cell-based functional validation and imaging analyses.
| Cat. No. | Product Name | Target | Sequence Region | Price |
| NPOE-001 | HEK293 Cell Line Overexpressing Nipah Virus Glycoprotein G | Glycoprotein G | 1–602 | Inquiry |
| NPOE-002 | HEK293 Cell Line Overexpressing Nipah Virus Fusion Glycoprotein | Fusion Glycoprotein | 1–546 | Inquiry |
Creative Biogene offers a panel of research-grade antibodies targeting NiV G and F proteins, available in IgG, Fab, and scFv formats. These antibodies support epitope mapping, neutralization, and blocking assays, and the development and optimization of ELISA, immunofluorescence, and related analytical methods.
| Cat. No. | Product Name | Target | Tag / Format | Price |
| NPA-001 | Anti-Nipah Virus Glycoprotein G (HENV-26) | Glycoprotein G | Mouse IgG1 | Inquiry |
| NPA-002 | Anti-Nipah Virus Glycoprotein G (HENV-32) | Glycoprotein G | Mouse IgG1 | Inquiry |
| NPA-003 | Anti-Nipah Virus Glycoprotein G (nAH1.3) | Glycoprotein G | Fab | Inquiry |
| NPA-004 | Anti-Nipah Virus Glycoprotein G (m102.3) | Glycoprotein G | Fab | Inquiry |
| NPA-005 | Anti-Nipah Virus Glycoprotein G (m102.4) | Glycoprotein G | Fab | Inquiry |
| NPA-006 | Anti-Nipah Virus Fusion Glycoprotein (5B3) | Fusion Glycoprotein | scFv | Inquiry |
| NPA-007 | Anti-Nipah Virus Fusion Glycoprotein (Fab66) | Fusion Glycoprotein | Fab | Inquiry |
| NPA-008 | Anti-Nipah Virus Fusion Glycoprotein (1F5) | Fusion Glycoprotein | Fab | Inquiry |
| NPA-009 | Anti-Nipah Virus Fusion Glycoprotein (12B2) | Fusion Glycoprotein | Fab | Inquiry |
| NPA-010 | Anti-Nipah Virus Fusion Glycoprotein (14F8) | Fusion Glycoprotein | Fab | Inquiry |
These kits can be applied in in vitro model validation, methodological development, and molecular-level analyses. When used in combination with recombinant antigens and antibodies, they support the construction of multi-layered and cross-validated NiV research workflows.
| Cat. No. | Product Name | Price |
| NPD-001 | Nipah Virus PCR Detection Kit | Inquiry |
| NPD-002 | Nipah Virus qPCR Detection Kit | Inquiry |
Creative Biogene's Nipah virus research products are not a simple collection of isolated reagents, but rather a combinable and scalable toolkit designed around the mechanisms of NiV infection and pathogenesis. This portfolio supports:
As research on highly pathogenic viruses increasingly emphasizes biosafety, standardization, and reproducibility, Creative Biogene is committed to providing reliable, transparent, and literature-aligned solutions for Nipah virus research, facilitating the steady translation of fundamental discoveries toward applied outcomes.
References:
Copyright © Creative Biogene. All rights reserved.